Two new funding opportunity announcements (FOAs) will support studies on the medical, sociological, psychological, and structural causes and consequences of transgender and gender nonconforming identities: Research on the Health of Transgender and Gender Nonconforming Populations (R01) and Research on the Health of Transgender and Gender Nonconforming Populations (R21).
While the FOAs differ in their administrative details, both seek research projects in the areas of:
- Improved methodology and measurement to account for transgender and gender nonconforming people in research studies
- Development of transgender and gender nonconforming identities
- Improvements in diagnosis and clinical management of gender dysphoria
- Health outcomes of long-term hormone use and surgical treatment
- Quality of life and mental health
Within those broad topic areas, NIAID is especially interested in studies of HIV drug treatment and prophylaxis—including oral and injectable drugs, vaccines, and broadly neutralizing antibodies—and potential interactions with hormonal and surgical treatments.
Apply for an exploratory/developmental research grant (R21) if your research project will investigate novel scientific ideas or new model systems, tools, or technologies. Apply for the R01 if you already have preliminary data and are ready to begin a major research project.
R21 applicants may propose a maximum project period of two years. Your budget request cannot exceed $275,000 in direct costs for the two-year period and neither year can have a budget exceeding $200,000.
R01 applicants may propose a maximum project period of five years. Your budget is not capped, but should reflect the actual needs of your project.
Deadlines for both FOAs follow NIH’s standard Due Dates and AIDS and AIDS-Related Due Dates (depending on whether your application is AIDS-related). But take note: The earliest you can apply is for fiscal year 2019 Cycle I Due Dates, meaning February 5, 2018 for R01 applications, February 25, 2018, for R21 applications, and May 7, 2018, for AIDS-related R01 and R21 applications.
Contact Dr. Philip Renzullo if you have any questions.